Intelligent Ultrasnd - Notice of Results
08/08/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220808:nRSH1444Va&default-theme=true
RNS Number : 1444V Intelligent Ultrasound Group PLC 08 August 2022
Intelligent Ultrasound Group plc
(the "Group" or the "Company")
Notice of results
Analyst and investor briefing
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces it will issue its interim results for the six months
ended 30 June 2022 on Thursday 18, August 2022.
A briefing for analysts will be held via Zoom on 18 August 2022 at 9.30am. To
register, please contact Walbrook PR at intelligentultrasound@walbrookpr.com
(mailto:intelligentultrasound@walbrookpr.com) .
The Company will host a live presentation for investors given by Stuart Gall
and Helen Jones via the Investor Meet Company platform on Friday, 19 August
2022 at 2.30pm. The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am the day before the meeting or at any time
during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet the
Company via:
https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor
(https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor)
Investors who already follow Intelligent Ultrasound on the Investor Meet
Company platform will automatically be invited.
For further information, please contact:
Intelligent Ultrasound Group plc www. intelligentultrasound.com (http://intelligentultrasound.com/)
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor and Broker
Giles Balleny/Max Gould (Corporate Finance) Tel: +44 (0)20 7397 8900
Michael Johnson/Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
(mailto:intelligentultrasound@walbrookpr.com)
Anna Dunphy Mob: +44 (0)7876 741 001
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,400 simulators have been sold to c. 700 medical
institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.
www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
NOTE: ScanNav Anatomy PNB is CE approved, but not yet available for sale in
the US or any other territory requiring government approval for this type of
product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORZZGGRDKKGZZM